Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 213.0% in July

Posted by Brenda Bartman on Jul 28th, 2026

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 429,660 shares, a growth of 213.0% from the June 30th total of 137,273 shares. Based on an average daily volume of 7,541,738 shares, the short-interest ratio is currently 0.1 days. Approximately 77.1% of the shares of the stock are sold short.

Shuttle Pharmaceuticals Stock Performance

SHPH stock traded down $0.14 during trading on Tuesday, hitting $2.78. 49,386 shares of the company traded hands, compared to its average volume of 1,065,101. The company has a 50-day moving average of $4.13 and a 200-day moving average of $8.92. Shuttle Pharmaceuticals has a 1 year low of $2.71 and a 1 year high of $55.90. The firm has a market capitalization of $1.78 million, a PE ratio of -0.06 and a beta of 0.29.

Insider Transactions at Shuttle Pharmaceuticals

In other news, major shareholder Financial Lp Hrt purchased 8,266 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average price of $3.38 per share, with a total value of $27,939.08. Following the completion of the purchase, the insider directly owned 60,540 shares in the company, valued at approximately $204,625.20. This trade represents a 15.81% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders bought 53,398 shares of company stock worth $181,764 and sold 38,133 shares worth $132,128. 12.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at $26,000. Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at about $37,000. Ikarian Capital LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the third quarter worth about $357,000. Institutional investors own 4.58% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings lowered Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

View Our Latest Stock Report on Shuttle Pharmaceuticals

About Shuttle Pharmaceuticals

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .